Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT03038100IIINewly diagnosed stage III/IV ovarian cancer (neo-adjuvant or adjuvant and maintenance)A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsAlabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03180307IIINewly diagnosed stage III ovarian cancerA Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian CancerView DrugsCalifornia, Florida, Minnesota, Ohio, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
OTL38fluorescent imaging ligand OTL38Folate receptor imaging agent
NCT03642132IIINewly diagnosed stage III/IV non-mucinous ovarian epithelial cancer (neo-adjuvant or adjuvant and maintenance)A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab In Combination With Chemotherapy Followed By Maintenance Therapy Of Avelumab In Combination With The Poly (Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Previously Untreated Advanced Ovarian Cancer (Javelin Ovarian Parp100)View DrugsArizona, Arkansas, California, Illinois, New York, Ohio, Oregon, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
TalazoparibMDV3800, BMN-673, Talazoparib TosylatePARP inhibitor
NCT03602859IIINewly diagnosed stage III/IV non-mucinous ovarian epithelial cancer (neo-adjuvant or adjuvant and maintenance)ENGOT-0V44 The FIRST (First-line Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerView DrugsAlaska, Connecticut, Louisiana, Maryland, Ohio, South Dakota, Washington
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NiraparibMK4827, ZejulaPARP inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
TSR-042ANB011, anti-PD-1 monoclonal antibody TSR-042Blocks PD-L1/2 inhibition of T cells
NCT03737643IIINewly diagnosed stage III/IV high grade non-mucinous epithelial ovarian cancer (neo-adjuvant or adjuvant and maintenance)A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).View DrugsCalifornia, Colorado, Florida, Georgia, Illinois, Indiana, Maryland, Michigan, Missouri, Nevada, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT02437812IINewly diagnosed stage II-IV ovarian cancerA Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CarcinomaView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
MetforminFortamet, Glucophage, Glumetza, RiometAMP-activated protein kinase (AMPK) activator
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT02520154IINewly diagnosed stage III/IV high grade non-mucinous ovarian epithelial cancer (neo-adjuvant)Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02834975IINewly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant)Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant ChemotherapyView DrugsFlorida
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02766582IINewly diagnosed stage III/IV ovarian cancer after suboptimal debulking surgeryPhase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian CancerView DrugsWisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03073525IIAdvanced high grade serous, clear cell, or endometrioid ovarian cancerA Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological CancersView DrugsAlabama, Georgia, Michigan, Montana, New Hampshire, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
Gemogenovatucel-TVigil, bi-shRNA-furin/GMCSF-expressing autologous tumor cell vaccine, bi-shRNA-furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine, FANG vaccineImmune cell stimulator and TGFbeta inhibitor
NCT02033616IINewly diagnosed stage III/IV ovarian cancerPhase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary TherapyView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
TAA-loaded autologous dendritic cell vaccineAnti-tumor immune response
NCT03531645IINewly diagnosed stage III/IV low grade serous ovarian cancer (neo-adjuvant)Pilot Translation Study of Neoadjuvant Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous CarcinomaView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
FulvestrantFaslodex, ICI 182,780, ZD9238ER antagonist (SERD)
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitor
NCT03206645IbNewly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)Phase IB Study of Weekly Paclitaxel + Carboplatin With the BMI-1 Inhibitor PTC596 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
PTC596polycomb ring finger oncogene inhibitor PTC596, BMI1 inhibitor PTC596BMI1 inhibitor
NCT03206177IbNewly diagnosed, persistent, or recurrent ovarian carcinosarcomaFeasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or OvaryView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GalunisertibLY2157299TGFBR1 antagonist
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT02713386I/IINewly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsIllinois, Iowa, Maryland, Ohio, Oklahoma, Pennsylvania, Rhode Island, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
Ruxolitiniboral JAK inhibitor INCB18424, oral Janus-associated kinase inhibitor INCB18424, Jakafi, INCB18424JAK1/2 kinase inhibitor
NCT02726997I/IINewly diagnosed stage III/IV high grade non-mucinous epithelial ovarian cancer (neo-adjuvant)Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)View DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03394885I/IINewly diagnosed stage III-IV ovarian cancer (neo-adjuvant; inc expansion)Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian CancerView DrugsNorth Carolina
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03393884I/IINewly diagnosed stage III/IV epithelial ovarian cancer (neo-adjuvant)A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsAlabama, Missouri, Oklahoma, Pennsylvania, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
EGEN-001phIL-12-005/PPC
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT02933073INewly diagnosed stage III/IV ovarian cancer in remission after primary treatment or after secondary debulking of recurrence >12 months after last platinumA Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian CarcinomaView DrugsConnecticut
Drug(s) in Trial Other Drug Names Main Known Action
OncoImmunomeAnti-tumor immune response
NCT03245892INewly diagnosed suspected stage III/IV high grade serous ovarian cancer (neo-adjuvant)A Pilot Study of Nivolumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03607955INewly diagnosed stage III/IV ovarian cancer (neo-adjuvant)Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyView DrugsMissouri, Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action
AVB-S6-500GAS6 antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor